BioCentury
ARTICLE | Product Development

Correlates and Endpoints

October 26, 2009 7:00 AM UTC

Details matter. While the first reports on a combination HIV vaccine suggested proof that both a T cell and an antibody response are needed to provide protection, the complete data disclosed last week are far more ambiguous.

The problem with the RV144 trial of a combination HIV vaccine in Thailand is that there is no way of knowing both who was protected from infection - because it is unknowable who was exposed - or how individuals were protected...